Appointed to the Chair of Induction Healthcare in June 2022, Christopher has experience as Chief Executive Officer (CEO) and Chair of quoted companies, (both Main Market and AIM), and private businesses in the education, healthcare, services and technology sectors. He has significant experience supporting growth for businesses across the U.S., Europe, Asia, Latin America and the Middle East.
Christopher started his career in the British Army before joining The Boston Consulting Group as an analyst, leading to a variety of senior management positions at Baxter International, the US-based healthcare multinational. Christopher was CEO of several fast-growing venture capital backed healthcare businesses including Imutran Ltd, and Weston Medical plc, which he took through three venture capital funding rounds to an IPO on the Main Market of the London Stock Exchange in 2000.
In 2004, Christopher co-founded Iceni Capital LLP, a private equity / venture capital firm focused on providing capital and operational support to fast growing UK companies in the services sector. He has Chaired a number of high growth technology, healthcare and service companies including TQ Education & Training which was sold to Pearson plc, AirPortr, Sphonic Solutions (recently sold to Signicat AS), Bubble and Tristel plc.
Christopher holds an MA (hons) from the University of Oxford and an MBA from the Harvard Business School.
Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. Ian is currently Executive Chairman of Niox Group plc and was recently Senior Independent Director of Clinigen plc until its sale to Triton.
Previous roles include Executive Chairman of Bioquell PLC, non-executive Chairman of Redcentric plc, Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. and non-executive Director of Ergomed PLC. He has also served on the boards of various other public and private companies including Aim listed companies; Evans Analytical Group and AOI Medical Inc.
Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a Chartered Biologist, a Fellow of the Royal Society of Biology and a member of the Institute of Directors.
In addition to his role at Induction, Andy is chairman of Docly AB and a non-executive director at Logex Group. His most recent full time role was CEO of NHS Digital, the government body responsible for technology and data for the NHS.
Prior to that, his career was in the technology industry, holding a wide variety of senior roles in IBM, Alcatel-Lucent and CSC. He holds an MA in mathematics and engineering from Cambridge University.
Jane is Executive Chair of Diffblue Ltd and a non-executive director of The Sensible Code Company Limited. She also serves as an advisor for tech start-ups.
Previously she was CEO of Canonical for 7 years, which followed a 7 year period as COO of Canonical. With experience in the US, Japan and the UK, she has spent her entire career in software engineering and IT management, starting as a software developer and rising through various leadership roles. She holds a BS from Haverford College, an MS from Vanderbilt University, and an MBA from Oxford University.
Hugo has founded several healthcare and biotech services businesses including DrugDev (acquired by IQVIA) MediGuard (owned by IQVIA), Health Research Solutions (acquired by Quintiles, now IQVIA), and MedSeed (acquired by eHealthcare Asia).
Hugo served as full-time Executive Chairman, Product Lead and co-founder at DrugDev from 2012-2017. Previously, Hugo served as Vice President at Quintiles (now IQVIA) from 2002 to 2011.